BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH

Background: FGF21 is an endogenous hormone that regulates carbohydrate, lipid and energy metabolism. FGF21 analogs improve liver and metabolic abnormalities in non-alcoholic steatohepatitis (NASH). BIO89-100 is a long-acting glycoPEGylated FGF21, with promising tolerability and pharmacodynamic effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Frias, Juan Pablo, Lawitz, Eric J, Ortiz-LaSanta, Grisell, Franey, Bridgette, Morrow, Linda, Chen, Chao-Yin, Tseng, Leo, Charlton, R William, Mansbach, Hank, Margalit, Maya, Loomba, Rohit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Adipose Tissue, Appetite, and Obesity
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089146/
http://dx.doi.org/10.1210/jendso/bvab048.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089146/
http://dx.doi.org/10.1210/jendso/bvab048.010

Ejemplares similares